Neuropharmacology of the adenosine A2A receptors

Drug Development Research

Volumn 39, Issue 3-4, 1996, Pages 450-460

  Ongini, Ennio ^a,d   Dionisotti, Silvio ^a   Morelli, Micaela ^b   Ferré, Sergi ^c   Svenningsson, Per ^c   Fuxe, Kjell ^c   Fredholm, Bertil B ^c  

^a San Raffaele Science Park   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d San Raffaele Science Park   (Italy)

Author keywords

A2A adenosine receptors; A2A receptor antagonists; Dopamine adenosine interaction; KF 17837; SCH 58261

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; XANTHINE DERIVATIVE;

CONFERENCE PAPER; CORPUS STRIATUM; GENE EXPRESSION; HUMAN; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE;

EID: 0030435689     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199611/12)39:3/4<450::AID-DDR27>3.0.CO;2-3     Document Type: Article

References (89)

1. 2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol 294:383-389.
2. Agnati L, Ferré S, Cortelli P, Fuxe K (1995): A brief appraisal on some aspects of the receptor-receptor interaction. Neurochem Int 27:139-146.
3. 2A receptor mRNA is expressed by enkephalin cells hut not by somatostatin cells in rat striutum: A co-expression study. Miol Brain Res 22:204-210.
4. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 4:2539-2544.
5. 2Aadenosine antagonists. J Med Chem 39:1164-1171.
6. 3H]SCH 58261 to coronary artery membranes. Circ Res, 79:1153-1160.
7. 2A adenosine receptors on sleepwaking patterns in rats. Drug Dev Res 37:65-72.
8. 3H]-NECA in rat striatal membranes. Mol Pharmacol 29:331-346.
9. 2B subtype. J Neurochem 59:425-431.
10. 1-mediated heinodynamic effects. J Pharmacol Exp Ther 268:1506-1551.
11. 2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation. J Med Chem 37:1720-1726.
12. 2A adenosine receptor agonists. J Med Chem 38:1462-1672.
13. Cunha RA, Johansson B, van der Ploeg I, Sebastião AM, Ribeiro AJ, Fredholm BB (1994): Evidence for functionally important adenosine AZA receptors in the rat hippocampus. Brain Res 649:208-216.
14. 2A receptors. Naunyn-Schmiedeberg Arch Pharmacol 353:261-271.
15. 2 receptors in stably cotransfected fibroblast cells. Eur J Pharmacol, 316:325-333.
16. 3H]SCH 58261. J Pharmacol Exp Ther, 298:1209-1214.
17. 3H]-SCH 58261. Br. Pharmacol, in press.
18. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, TC Freeman (1996): Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468.
19. 2A receptors potentiates L-DOPA-induced turning behaviour and c-fos expression in unilaterally 6-hydroxydopamine lesioned rats. Eur J Pharmacol, in press.
20. 2 receptors in the neostriatum. Brain Res 594:124-130.
21. 2 receptors in rat striatal membranes. Proc Natl Aead Sci USA 88:7238-7241.
22. 2 receptors induces catalepsy. Neurosci Lett 130:162-164.
23. Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm B (1992): Adenosine-dopamine interactions in the brain. Neuroscience 51:501-512.
24. Ferré S, O'ConnorW, Fuxe K, Ungerstedt U (1993a): The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. J Neurosci 13:5402-5406.
25. 2 receptors in rat neostriatal membranes. Eur J Pharmacol 244:311-315.
26. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63:765-773.
27. 2 receptors in the neostriatum. Psychopharmacology 116:279-284.
28. Fredholm BB (1977): Activation of adenylate cyelase from rat striatum and tuberculum olfaetorium by adenosine. Med Biol 55:262-267.
29. Fredholm BB, Fuxe K, Aguati L (1976): Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur J Pharmacol 38:31-38.
30. Fredholm BB, Abbracchio MR Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994): Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
31. 2 receptors mediate the inhibitory effect of adenosine on fMLP-stimulated respiratory burst in neutrophil leukocytes. Naunyn-Schmiedeberg Arch Pharmacol 354:262-267.
32. 2 dopamine receptors in rat striatum. Mol Brain Res 14:186-195.
33. Fuxe K, Ungerstedt U (1974): Action of caffeine and theophyllamine on supersensitive dopamine receptors: Considerable enhancement of receptor response to treatment with L-dopa and dopamine agonists Med Biol 52:48-54.
34. 2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug Dev Res 28:374-380.
35. Gatta F, Del Giudice MR, Borioni A, Borea PA, Dionisotti S, Ongini E (1993): Synthesis of imidazo [1,2-c]pyrazolo [4,3-e]pyrimidines, pyrazolo [4,3-e]1,2,4 triazolo[1,5-c]pyrimidines and triazolo[5,1-i]purines: New potent Aoadcnosine receptor antagonists. Eur J Med Chem 28:569-577.
36. Gurden MF, Coates J, Ellis F, Evans B, Foster M, Hornby E, Kennedy I, Martin DR Strong P, Vardey CJ, Wheeldon A (1993): Functional characterization of three adenosine receptor types. Br J Pharmaeol 109:693-698.
37. 2A adenosine receptors from rat striatum and rat pheochroniocytoma PC12 cells: Characterization with radioligand binding and by activation of adenylate cyclase. Mol Phannacol 41:352-359.
38. Hughes P, Dragunow M (1995): Induction of immediate-early genes and the control of neurotransniitter-regulated gene expression within the nervous system. Pharmaeol Rev 47:133-178.
39. Jacobson KA, Van Galen PJM, Williams M (1992): Adenosine receptors: Pharmacology, structure-activity relationship and therapeutic potential. J Med Chem 35:407-422.
40. 2 selective adenosine antagonists. J Med Chem 36:1333-1342.
41. 2-adenosine antagonist in vitro and in vivo. FEBS Lett 323:141-144.
42. 3H]CGS 21680. Eur J Pharmacol 168:243-246.
43. 2 receptors in rat brain. J Pharmacol Exp Ther 251:888-893.
44. 3H]CGS 21680 to rat brain using antoradiography. Neuropharmacology 34:393-403.
45. 3H]CGS 21680 to rat cortex differs from its binding to rat striatum. Eur J Pharmacol 247:103-110.
46. Johansson B, Lindström K, Fredholm BB (1994): Differences in the regional and cellular localization of c-fos messenger RNA induced by amphetamine., cocaine and caffeine in the rat. Nenroscience 59:837-849.
47. 1 mRNA in mouse brain. Effect of long term caffeine treatment. Brain Res, in press.
48. 2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256:263-268.
49. 1 dopamine receptor gene. Proc Natl Acad Sci USA 88:4205-4209.
50. Libert F, Pamentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, Simons M-J, Dumont JE, Vassart G (1989): Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 244:569-572.
51. 2 receptor with physiological constitutive activity. Biochem Biophys Res Commun 173:1169-1178.
52. 2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 42:697-706.
53. 2A adenosine receptor agonist, 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneim Forsch Drug Res 12:1296-1304.
54. 2A adenosine antagonist SCH 58261 in the rat and rabbit. Br J Pharmacol 117:279P.
55. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine lesioned rats. Neuroscience 67:48-55.
56. 2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 251:21-25.
57. 2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methy]xanthine. J Med Chein 36:3731-3733.
58. 2 receptor antagonist. Eur J Pharmacol 267:335-341.
59. 2 receptor antagonist to rat brain membranes. Mol Pharmacol 46:817-822.
60. Ögren SO (1996): The behavioural pharmacology of typical and atypical antipsychotic drugs. In Csernansky JG (ed.): Handbook of Experimental Pharmacology. Berlin: Springer, Vol. 120, pp 225-266.
61. Olsson RA, Thompson RD, Silvia SK, Ueeda M (1992): 2-(N′-alkylidenehydrazno) adenosines: Potent and selective coronary vasodilators. J Med Chem 35:4557-4561.
62. 2A receptors. Trends Pharmacol Sci 17:364-372.
63. 2 adenosine receptors by two antipeptide antibody preparations. Mol Pharmacol 42:391-397.
64. 3H]-CGS 21680 as a ligand. Naunyn-Schmiedeberg Arch Pharmacol 342:85-89.
65. 2 receptors and nitrobenzylthioinosine-scnsitive transporters in gerbil brain: No changes following long-term treatment with the adenosine transport inhibitor propentofylline. Neuropharmacology 35:79-89.
66. 2A adenosine receptor gene. J Neurochem 66:362-368.
67. 2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705:79-84.
68. 1 agonists in dopamine-denervated rats. Eur J Neurosci 8:1176-1181.
69. 2A selective adenosine antagonist. Br J Pharmacol 115:1096-1102.
70. Premont J, Perez M, Blanc G, Tassin JP, Thierry AM, Herve D, Bockaert J (1979): Adenosine-sensitive adenylate cyclase in rat brain hoinogenates: Kinetic characteristics, specificity, topographical, subcelInlar and cellular distribution. Mol Phannacol 16:790-804.
71. 2A agonists: A potential new type of atypical neuroleptics. Neuropsychopharmacology, in press.
72. Sagar SM, Sharp FR, Outran T (1988): Expression of c-fos protein in brain: Metabolic mapping at the cellular level. Science 240:1328-1331.
73. 1 dopamine receptor. Brain Res 519:333-337.
74. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 57:1062-1067.
75. 2 receptor mRNA in the human brain. Neurosci Lett 130:177-181.
76. 2 antagonists. J Med Ghent 36:2342-2345.
77. Svenningsson P, Nomikos GG, Fredholm BB (1995): Biphasit changes in locomotor behavior and in expression of inRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci 15:7612-7624.
78. Svenningsson P, Hall H, Sedvall G, Fredholm BB (1997): Distribution of adenosine receptors in the post-mortem human brain. An autoradiographic study. Synapse, in press.
79. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of mRNA for NGF1-A and NGF1-B in caudate-pntamen and nucleus acciunbens. Neuroscience, in press.
80. 2 adenosine receptor. J Med Chem 34:1340-1344.
81. 2 receptors in Jurkat cells and PG12 cells using adenosine receptor agonists. Nauuyn-Schmicdeberg Arch Pharmacol 353:250-260.
82. 2A adenosine receptors. J Med Chem, 39:4211-4217.
83. 2A adenosine receptor gene expression in developing rat brain. Mol Brain Res 20:313-327.
84. Weaver DR, Reppert SM (1992): Adenosine receptor gene expression in rat kidney. Am J Physiol 263:F991-F995.
85. Williams M, Francis J, Ghai G, Braunwalder A, Psychoyos S, Stone GA, Cash WD (1987): Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non xanthine adenosine antagonist. J Pharmacol Exp Ther 241:415-420.
86. 2 (long-form) receptor co-transfeeted mouse fibroblast cell lines: Studies on intracellular calcium levels. Neuroscience 68:729-736.
87. 3H]-5′-N-ethylcarboxanmle adenosine binds to both Ra and Ri adenosine receptors in rat striatum. NaunynSchmiedeberg Arch Pharmacol 325:218-225.
88. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 276:398-404.
89. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 117:1381-1386.